drospirenone: Clinical Trials

16 trials of drospirenone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 1 unknown. 16 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 316Completed 15, Unknown 1
Phase 21Completed 1

Follow drospirenone: new trials by email Literature Review of drospirenone trials Research Report on drospirenone

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
Drospirenone - Contraception, Change in Bone Mineral Density
Phase 3CompletedInsud Pharma15422022-08-022025-10-08
The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS.
Lifestyle intervention, Probiotic Agent, Oral contraceptive - Polycystic Ovary Syndrome
Phase 3UnknownPeking Union Medical College Hospital2002019-02-212019-10-10
LCS16 vs. COC User Satisfaction and Tolerability Study
Levonorgestrel (Kyleena, BAY86-5028), Ethinyl estradiol and drospirenone (Yarina, BAY86-5131) - Contraception
Phase 3CompletedBayer1452017-03-132023-06-18
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study
15 mg E4/3 mg DRSP - Contraception
Phase 3CompletedEstetra21482016-08-302020-02-10
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study
15 mg E4/3 mg DRSP - Contraception
Phase 3CompletedEstetra15772016-06-012019-10-04
Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
LF111 (drospirenone) - Contraception
Phase 3CompletedLaboratories Leon Farma, S.A.15522014-10-092019-08-06
A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)
ENG 120 µg + EE 15 µg intravaginal ring, DRSP 3 mg + EE 30 µg - Contraception
Phase 3CompletedOrganon and Co9832011-09-192024-06-20
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
drospirenone and ethinyl estradiol, Placebo tablet - Acne Vulgaris
Phase 3CompletedMassachusetts General Hospital302009-04-012013-03-05
Endometrial Safety Study
0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella) - Postmenopause
Phase 3CompletedBayer6622007-08-012014-12-31
Efficacy and Safety Study for an Oral Contraceptive Containing Folate
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz) - Neural Tube Defects, Contraception
Phase 3CompletedBayer3852007-04-012014-04-23
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg) - Vasomotor Symptoms, Hot Flashes
Phase 3CompletedBayer7352007-03-012015-05-06
Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea
DRSP 3 mg/EE 20 µg (13 cycles), DRSP 3 mg/EE 30 µg (6 cycles) - Dysmenorrhea
Phase 2 / Phase 3CompletedBayer4202007-02-012013-01-24
Efficacy and Safety Oral Contraceptive Study
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) - Contraception
Phase 3CompletedBayer11132004-03-012014-12-31
Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo - Acne Vulgaris
Phase 3CompletedBayer5342003-01-012014-12-30
Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo - Acne Vulgaris
Phase 3CompletedBayer5412003-01-012014-12-30
Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.
Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131) - Healthy
Phase 3CompletedBayer2212002-12-012013-10-11

Conditions studied

Acne Vulgaris (3)  ·  Hot Flashes (2)  ·  Contraception Behavior (1)  ·  Dysmenorrhea (1)  ·  Neural Tube Defects (1)  ·  Polycystic Ovary Syndrome (1)

Sponsors

Bayer (9)  ·  Estetra (2)  ·  Insud Pharma (1)  ·  Laboratories Leon Farma, S.A. (1)  ·  Massachusetts General Hospital (1)  ·  Organon and Co (1)  ·  Peking Union Medical College Hospital (1)

Countries

United States (9)  ·  Canada (2)  ·  Russia (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  China (1)  ·  Denmark (1)  ·  Italy (1)  ·  Japan (1)  ·  Mexico (1)

Top investigators

Enrico Colli, MD (2)  ·  Alexandra B. Kimball, MD, MPH (1)  ·  Rong Chen, Ph. D. (1)

Results publications

PMID 37023457, PMID 18827119, PMID 21277674, PMID 21288628, PMID 21721590, PMID 21903192, PMID 22067790, PMID 22228322, PMID 23531117, PMID 23534865, PMID 23963307, PMID 23963309, PMID 24105751, PMID 27093642, PMID 27339759, PMID 29370410, PMID 33008401, PMID 37523477